Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Insulin for Dry Eye Disease in Diabetics
NCT04877210Phase 1Unknown
- Sponsor
- Hospital Canselor Tuanku Muhriz
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of Generex Oral-lyn in dry eye disease (DED) (3 arms), sponsored by Hospital Canselor Tuanku Muhriz. Primary endpoints: Interleukin 1a at 4 weeks, Interleukin 6 at 4 weeks and 1 more. Status: unknown.
02
Drugs
Generex Oral-lyn
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04877210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877210.